// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years

W. Sandborn - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ustekinumab

Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

L. Peyrin-Biroulet - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Etrolizumab

Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study

R. Kalla - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014

O. Oln - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease

C. Lahiff - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Gut specific regulatory T cells – a new frontier for Crohn's disease therapy

R. Goldberg - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Tretinoin

Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease

A. Lewis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

European Crohn's and Colitis Organisation topical review on environmental factors in IBD

C. Maaser - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO

R. Sigall Boneh - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study

V. Svolos - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

S. Travis - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

N/A

Adalimumab

Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis

B.G. Feagan - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study

S. Vermeire - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review

R. Ehehalt - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Vedolizumab clinical and post-marketing safety experience of opportunistic infections

S.C. Ng - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters

A. Stallmach - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

A model for prediction of early surgery and complications in paediatric Crohn's disease: results of the prospective GROWTH CD study

A. Levine - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker

J. Lee - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease

G. Sellge - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Methadone hydrochloride

Results of the Fifth Scientific Workshop of the ECCO (II): clinical aspects of perianal fistulising Crohn's disease – the unmet needs

K. Gecse - European Crohn’s and Colitis Organisation (ECCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved